Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 22.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
21.00 23.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.11 5.04 9.16 2.3 35
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Summit Therapeutics (SUMM) Latest News

More Summit Therapeutics News
Summit Therapeutics Takeover Rumours

Summit Therapeutics (SUMM) Share Charts

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Intraday Summit Therapeutics Chart

Intraday Summit Therapeutics Chart

Summit Therapeutics (SUMM) Discussions and Chat

Summit Therapeutics (SUMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Summit Therapeutics trades in real-time

Summit Therapeutics (SUMM) Top Chat Posts

DateSubject
15/9/2019
09:20
Summit Therapeutics Daily Update: Summit Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Therapeutics was 22p.
Summit Therapeutics Plc has a 4 week average price of 18.50p and a 12 week average price of 18.50p.
The 1 year high share price is 37p while the 1 year low share price is currently 17.50p.
There are currently 160,494,758 shares in issue and the average daily traded volume is 62,235 shares. The market capitalisation of Summit Therapeutics Plc is £35,308,846.76.
12/6/2019
17:46
kirk 6: Less spend tho and just under 28m in cash surely if the trials are successful Summ can partner?!?What about the recent £1.50 share price target ?
23/5/2019
13:21
hugus maximus: Interesting to see this follow up Waterloo. I think many who followed Summit's Ezutromid development were astounded by the way in which Sarepta's Exondys 51 made it on to the market under such dodgy circumstances and pushed the company's share price up ridiculously in the process. I wonder if Dame Kay Davies's work is set to ever reap reward? What a tragedy.
25/3/2019
15:00
kirk 6: All these articles seem extremely up near for Summ however the more articles they get posted the lower the share price goes. Back in to the debths again now from hitting 34p a few weeks ago
14/3/2019
11:06
football: Summit Therapeutics plc Summit Highlights Use Of Discuva Platform In Identifying New Mechanism Antibiotics Against Neisseria ... Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference -- N. Gonorrhoeae and ESKAPE Pathogens Identified as High Priority by the US CDC and the WHO https://uk.advfn.com/stock-market/london/summit-corp-SUMM/share-news/Summit-Therapeutics-plc-Summit-Highlights-Use-Of-D/79470756
05/3/2019
10:13
football: Doesn't always happen but share price does go blue a lot just before any news comes out and seeing we was down in the US last night it's strange that were going up this side of the pond today
30/1/2019
20:38
lagosboy: That's all good stuff and hardly new , but it never translates into an increase in Summ's share price which is what we are all here for. Endless links to this sort of stuff halve been posted for years now. Why ?
02/1/2019
12:41
wildbunch: Assuming no more dilution (a big, big if)then each £1bn of market cap = £6 share price. That is £3 for Mr Robert W Duggan and £3 for the rest of us. If drug works well and some of rest of pipeline works then market cap will be well north of £1bn. BUT lagosboy has a point- why would Duggan want to share with the rest of us if he can avoid that? The one thing in our favour is the 2.5m (approx) options @ 29.5p owned by our CEO. But one can imagine a scenario where the company is taken private with the CEO still employed with a new arrangement which leaves him no worse off. I can see Waterloo's point about current valuation being low on short term basis but am deeply sceptical about us being able to enjoy a potential a long term 30+ bagger. I am long term holder at average of around £1.5 so will continue for the ride!
28/12/2018
14:49
lagosboy: Deal with SRPT, that as way to late as you well know and was merely a punt heavily favouring SRPT for their own shareholders. In any event its dead now anyway, so how you reach the conclusion that is was a good deal is beyond my logic. By the time Summ get anything to market the bacteria will have mutated and it will be ineffective or have such a short useful life that no pharma will be interested anyway. Barda is a driven by political considerations as much as medical ones. Whoopee for Glyn, such a great deal that the share price has roared. As for cash- my point is $25m or whatever the figure is now for Summ is irrelevant in the context of the future funding that will be necessary. If Summ was sitting on a cash runway of $250m plus that would be a different matter. $25m will barely cover Glyn's salary, air travel and conference attendance!
19/12/2018
07:58
waterloo01: Thanks for that. Summit Therapeutics (SUMM) What have shares done? Summit has not had a good year. Shares fell off a cliff in June from 195p to 36.9p. They have recovered slightly to sit at 20.3p. What’s its current market cap? £14.8m. What was cash at last count? The company had cash and cash equivalents of £13m on 31 October 2018. However, earlier this week it announced that it would raise $25m by selling American Depositary Shares in a private placement. What’s next? As we have noted before, the biotech firm fell by as much as 80pc in July. This came after it revealed that it had discontinued its treatment for Duchenne Muscular Dystrophy. Despite this setback, the firm has been working to move forward. It is now focusing on the development of the three antibiotics left in its pipeline. This week, the business announced a whopping $25m placing. The funds will support a critical phase three clinical programme for ridinilazole. This is an antibiotic for colon infection C. Difficile. Unlike similar medications, it does not cause damage to natural gut flora during treatment. The money will also advance studies for the treatment of gonorrhoea. As Summit has demonstrated, investing in pharma businesses can be a bit like roulette. This is because these businesses often completely hang on the outcome of trials and the whim of regulators. If this is of interest, then Summit’s ambitious work programme could generate some significant share price movement.
21/5/2018
13:27
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
Summit Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190916 06:16:01